Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x100px
Document › Details

Hybrigenics S.A.. (4/28/17). "Press Release: Hybrigenics Full Year 2016 Results". Paris.

Organisations Organisation Hybrigenics S.A. (Euronext Paris: ALHYG)
  Group Hybrigenics (Group)
  Organisation 2 Hybrigenics Services S.A.S.
  Group Biofiteam (Group)
Products Product inecalcitol
  Product 2 proteomic services
Index term Index term Hybrigenics–Biofiteam: investment, 201703 management buy-out 75.8% €196k cash + €600k milestones of Hybrigenics Services from Hybrigenics SA
Persons Person Delansorne, Rémi (Hybrigenics 201110 CEO)
  Person 2 Perez, Julien (NewCap. 201509)

> Doubling of the turnover of retained activities

> Cash burn of retained activities reduced by half

> Cash position of EUR 8.5 million as of December 31st, 2016?

Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new anticancer treatments, today announces its consolidated results for the full year ended December 31st, 2016.

Hybrigenics’ annual results take into account the recent sale of its controlling stakes in Hybrigenics Services, its subsidiary dedicated to proteomic scientific services (cf. press release of March 13th, 2017), which constitute the discontinued operations. The development of inecalcitol, the research on ubiquitin-specific proteases and the genomic scientific services performed by the Helixio branch, represent Hybrigenics’ retained activities.

IFRS (EUR million)


Other operating revenuesb

Total operating revenues

Total operating costs

Other operating costs and revenues

Operating loss

Net profit from discontinued activities

Net loss from retained activities

Net loss

Cash burn of retained activities

Cash position of retained activities (at year end)

a) restated from the impacts of the sale of the controlling stakes in Hybrigenics Services

b) revenues from subleases, services to subleasers and current year research tax credit

The turnover of retained activities has more than doubled with a EUR 1.5 million payment received as milestone in the drug discovery research collaboration with Servier in the field of ubiquitin-specific proteases (cf. press release of October 10th, 2016). It represents most of the 64% increase in total operating revenues from EUR 2.2 to 3.6 million. Operating costs have increased by 13% from EUR 7.0 to 7.9 million due to the launch of the clinical Phase II study of inecalcitol in acute myeloid leukemia in France and in the United States. The operating loss decreased by 14% from EUR 5.0 to 4.3 million. The net loss increased by 23% from EUR 4.3 to 5.3 million, due to a EUR 1.1 million provision for capital loss related to the sale of Hybrigenics Services shares, and to the decrease of 83% from EUR 0.6 to 0.1 million of the net profit of the discontinued activities.

The cash consumption of retained activities has been limited to EUR 2.6 million as compared to EUR 6.0 million in 2015, thanks to the Servier milestone and the research tax credit, both received in the second half of 2016.

As of December 31st, the cash position of Hybrigenics’ retained activities was EUR 8.5 million vs. EUR 11.7 million as of December 31st, 2015.

“Hybrigenics’ retained activities, focused on biopharmaceutical Research and Development against cancer, has recorded a strong revenue growth, thanks to a milestone payment in its research collaboration with Servier. The new scope of the company allows to prioritize investments for the clinical development of inecalcitol, while optimizing cash consumption,” said Remi Delansorne, Hybrigenics’ CEO.

Hybrigenics ( is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases.

Hybrigenics’ development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Inecalcitol has been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. Two clinical Phase II studies of inecalcitol are currently ongoing in chronic myeloid leukemia and acute myeloid leukemia. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication.

Hybrigenics’ research program is exploring the role of enzymes called Ubiquitin-Specific Proteases (USP) in the balance between degradation and recycling of proteins called onco-proteins due to their involvement in various cancers. Hybrigenics is evaluating the interest of inhibitors of USP as anti-cancer drug candidates. Hybrigenics has collaborated with Servier on one particular USP in oncology. In this R&D program, two milestones have been reached and additional milestones may be achieved until registration of a potential drug.

Hybrigenics Pharma Inc., based in Cambridge, Mass., is the U.S. subsidiary of Hybrigenics.

Hybrigenics is listed on the Alternext market of Euronext Paris
ISIN: FR0004153930
Ticker: ALHYG

Rémi Delansorne
Tel.: +33 (0)1 58 10 38 00

Financial communication
Julien Perez / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94

Record changed: 2023-06-05


Picture EBD Group ChinaBio Partnering Forum 2023 Shanghai 650x200px

More documents for Hybrigenics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x300px

» top